Back to search

IS-AUR-Samarb.progr. Norge Frankrike

Development and validation of CXXC5/RINF (Retinoid Inducible Nuclear Factor) as a prognostic and therapeutic target in leukemia.

Awarded: NOK 53,856

CXXC5/Retinoid-inducible nuclear factor (RINF) is a gene located at the 5q31.2 chromosomal region, its function is not known but it seems to be involved in regulation of apoptosis and high expression is associated with chemoresistance and adverse prognosi s in human malignancies, i.e. breast cancer and acute myeloid leukemia (AML). In the present collaboration we will investigate the role of CXXC5/RINF in human AML. Based on a detailed biological characterization of human AML cells from a Norwgian biobank we will analyse correlations between CXXC5 expression and the expression of other genes identified by global gene expression profiles, protein profiles associated with risk of AML reapse after chemotherapy, leukemic cell differentiation analysed by membra ne molecule expression, proliferative capacity and cancer cell methabolism. The French collaborators have a main scientific focus on all aspects of RINF biology, and by using their technological repertoire and the experimental AML models available it will then be possible to investigate the effects of (i) RINF knockdown on important cellular functions/gene expression/molecular functions identified in the examination of the Norwegian cohort; and (ii) knockdown of identified markers can be used as a functio nal validation to investigate molecular crosstalk and the effects on CXXC5/RINF expression.

Funding scheme:

IS-AUR-Samarb.progr. Norge Frankrike